70. Breen AP, Murphy JA. Reactions of oxyl radicals with DNA. Free Radic Biol Med. 1995; 18: 1033-37.
71. Kemp JA. Cholecystectomy and colon cancer. Am J Gastroenterol. 1999; 94:1-2.
72. Henrikson CK, Argenzio RA, Liacos JA, Khosla J. Morphologic and functional effects of bile salt on the porcine colon during injury and repair. Lab Invest. 1989; 60: 72-87.
73. Sakaguchi M, Minovra T, Hiramatsu Y, Takada H, Yamamura M, Hioki K, et al. Effects of dietary saturated and unsaturated fatty acids on fecal bile acids and colon carcinogenesis induced by azoxymethane in rats. Cancer Res. 1986; 46: 61-5.
74. Dolara P, Cademi G, Salvadori M, Morozzi G, Fabiani, et al. Fecal levels of short-chain fatty acids and bile acids as determinants of colonic mucosal cell proliferation in humans. Nutr Cancer. 2002; 42 (2): 166-90.
75. Samaha H, Bernstein C, Payne C, Garewal H, Sampliner R, Bernstein H. Bile salt induction of apoptosis in globet cells of the normal human colonic globet cells: relevance to colon cancer. Acta Microsc. 1995; 4: 43-58.
76. Garewal H, Bernstein H, Bernstein C, Sampliner R, Payne C. Reduced bile acid-induced apoptosis in “normal” colorectal mucosa: a potential biological marker for cancer risk. Cancer Res. 1996; 56: 1480-3.
77. Mamianetti A, Garrido D, Carducci CN, Vescina MC. Excreción de ácidos biliares en pacientes con litiasis vesicular. Medicina (Bnos. Aires). 1999; 59: 269-73
78. Padmanabhan PN. Role of bile acids and neutral sterols in carcinogenesis. Am J Clin Nutr. 1988; 48: 768-74
79. Paniagua EM, Roque LJ, Cerdán CA, Rodríguez MA. Determinación de ácidos biliares totales en heces fecales en pacientes con neoplasia de colon y pólipos adenomatosos. Acta Gastroenterol Latinoam. 1994; 24: 99-104.
80. Hill MJ. Endogenous carcinogens. Practitioner.1981; 225: 803-9.
81. De Rubertis FR. Bile, eicosanoides and proliferation of colonic cell. Gastroenterology 1985; 89: 443-4.
82. Paniagua M, Valdés L, Cendán A. Acción de la celulosa microcristalina en la excreción de los ácidos biliares totales en heces fecales. Acta Gastroenterol Latinoam. 1996; 26: 173-6.
83. Paniagua M, Piñol F, Acosta E, Borbolla E, Cendán A. Acción de la celulosa microcristalina en pacientes con síndrome de intestino corto y ácidos biliares totales elevados en heces fecales. AIGE. 2002; 2: 4-7.
84. Doll R. The geographical distribution of cancer. Br J Cancer. 1969; 23: 1- 8.
85. Wynder EL, Shigematsu T. Environmental factor of cancer of the colon and rectum. Cancer. 1967; 20: 1520-61.
86. Grudy SM, Ahrens EH, Miettinen TA. Quantitative isolation and gas-liquid chromatographic analysis of total faecal bile acids. J Lipid Res. 1965; 6: 397-410.
87. Hepner GW, Hofmann AF, Malagelada JR, Szczepanik PA, Klein PD. Increased bacterial degradation of bile acids in cholecystectomized patients. Gastroenterology. 1974; 66: 556- 64.
88. Hikasa Y, Tanida N, Ohno T, Shimoyama T. Faecal bile acid profiles in patients with large bowel cancer in Japan. Gut. 1984; 25: 833- 8.
89. Tanida N, Hikasa Y, Shimoyama T, Setchell KD. Comparison of faecal bile acid profiles between patients with adenomatous polyps of the large bowel and healthy subjects in Japan. Gut 1984; 25: 824-32.
90. Makino T. Faecal bile acid excretion in patients with colon cancer, colon polyp and peptic ulcer. Tokai J Exp Clin Med. 1984; 9: 297-305.
91. Tanida N, Hikasa Y, Shimoyama T, Setchell KD. Faecal bile acid profiles of Japanese patients with adenomatous polyps of the large bowel: special reference to distribution, multiplicity, size and degree of dysplasia of the polyps. Jpn J Cancer Res. 1985; 76: 104-112.
92. KaleK HD, Stellard F, Kruis W, Paumgartner G. Detection of increased bile acid excretion by determination of bile acid content in single stool samples. Clin Chim Acta. 1984; 140: 85-90.
93. Breuer NF, Dommes P, Jaekel S, Goebell H. Faecal bile acid excretion pattern in colonic cancer patients. Dig Dis Sci. 1985; 30: 852-9.
94. Iwasaki Y, Arai K, Katayanagi S, Takahashi K, et al. Biomarkers for neoplasms in digestive organs. Gan To Kagaku Ryoho. 2004; 31 (7): 1015-20.
95. Summerton J, Flynn M, Cooke T, Taylor I. Bile acid receptors in colorectal cancer. Br J Surg. 1983; 70: 549-51.
96. Lapré JA, Van der Meer R. Diet–induced increase of colonic bile acids stimulates lytic activity of fecal water and proliferation of colonic cells. Carcinogenesis. 1992; 13: 41-4.
97. Latta RK, Fiander H, Ross NW, Simposon C, Schneirder H. Toxicity of bile acids to colon cancer cell lines. Cancer Lett. 1993; 70: 167-73.
98. Kamano T, Matsumoto M, Kano M. Diagnostic significance of measurement of fecal bile acids in colorectal cancer patients. Curr Therap Res. 1994; 55: 997-1001.
99. Kaibara N, Sasaki T, Ikeguchi M, Koga S, Ikawas S. Fecal bile acids and neutral sterol in Japanese with large carcinoma. Oncology. 1983; 40: 255-58.
100. Perogambros A, Legakis NJ. Faecal bile acids in patients with colon cancer. Zentralbl Bakteriol Mikrobiol Hyg (B). 1982; 176: 346-48.
101. Capron JP. Cholelithiasis and colon cancer. Concours Med. 1983<105:1935-50.
102. Haives A, Hill MJ, Thompson MH, Owen RW, Williams RE. A prospective study of faecal bile acids and colorectal cancer. Eur J Cancer Prev. 2000; 9: 317-23.
103. Ochsenkuhn T, Bayerdorffer E, Meining A, Schinkel M, Thiede C, Nussler V, et al. Colonic mucosal proliferation is related to serum deoxycholic levels. Cancer. 1999; 15: 1664-9.
104. Lagergren J, Ye W, Ekbom A. Intestinal cancer after cholecystectomy is bile involved in carcinogenesis? Gastroenterology. 2001; 121 (3): 542-7. 1992; 35: 24-8.
105. Novell F, Moral A, Pascual S, Trias M. Is there a relationship between cholelitiasis and colorectal cancer? Rev Esp Enferm Dig. 1995; S7 (4): 294-7.
106. Zeng ZS, Zhang ZF. Cholecystectomy and colorectal carcinoma in China. Surg Oncol. 1993; 2 (6): 311-9.
107. Goldbohm RA, Van Den Brandt PA, Van´t P, Dorant E, Sturmans F, Hermus RJ. Cholecystectomy and colorectal cancer: evidence from a cohort study on diet and cancer. Int J Cancer. 1993; 53 (5): 735-9.
108. Ekbom A, Yuen J, Admi HO, McLaughlin JK, Chow WH, Persson I, et al. Cholecystectomy and colorectal cancer. Gastroenterology. 1993; 105: 142-7.
109. Giovannucci E, Colditz GA, Stampter MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology. 1993; 105:130-41.
110. Soltero E, Cruz NI, Nazario CM, López RE, Alonzo A. Cholecystectomy and right colon cancer in Puerto Rico. Cancer 1990; 66: 2249-52.
111. Alonzo G, Lozzi D, Szram H, Romero I, Danadee Ras N, Fernández JL, et al. Factores asociados con displasia de alto grado y cáncer en adenomas colorrectales. Acta Gastroenterol Latinoam. 1995; 25: 131-5.
112. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Looftus Jr EV. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4 (3): 335-42.
113. Munkholm P, Loftus Jr EV, Reinacher-Schick A, Kombluth A, Mittmann V, Esendal B. Prevention of colorectal cancer in inflammatory bowel disease: Value of screening and 5- aminosalicylates. Digestion. 2006; 73 (1): 11-19.
114. Kiesslich R, Hoffman A, Neurath HF. Colonoscopy, tumors, and inflammatory bowel disease-new diagnostic methods. Endoscopy. 2006; 38 (1): 5-10.
115. Dixon A, Wusm P, art A, Robinson R. Distal adenomatous polyps are rare in patients with inflammatory bowel disease. Postgrad Med J. 2006; 82 (963): 76-8.
116. Moum B, Ekbom A. Ulcerative colitis, colorectal cancer and colonoscopy surveillance. Scand J Gastroenterol 2005; 40 (8): 881-5.
117. Bafandeh Y, Daghestani D, Esmaili H. Demographic and anatomical survey of colorectal polyps in an Iranian population. Assian Pac J Cancer Prev. 2005; 6 (4): 537-40.
118. Odom SR, Duffy SD, Barone JE, Ghevariga V, Mc Clane SJ. The rate adenocarcinoma in endoscopically removed colorectal polyps. Am Surg. 2005; 71(12): 1024-6.
119. Alrawi SJ, Schiff M, Carroll RE, Dayton M, Gibbs JF, et al. Aberrant crypt foci. Anticancers Res. 2006; 26 (1A): 107-19.
120. Takayama T, Miyanishi K, Hayashi T, Kukitsn T, et al. Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness. Clin Gastroenterol Hepatol. 2005; 3(7): 542-5.
121. Yabana T, Goto A, Arimura Y, Shimonura Y, Imai K. Genetic testing and gene based testing for colorectal cancer. Nippon Rinsho. 2005; 63 (12 Suppl): 217-22.
122. Homa K. Acceptance of screening colonoscopy for the prevention of colorectal cancer. Ann Acad Med Stelin. 2004; 50 (2): 55- 63.
123. Horford WV. Colorectal cancer screening and surveillance. Sur Oncol Clin N Am. 2006; 15 (1): 1-20.
124. Bernstein MA, Feczko PJ, Halpert RD, Simms SM, Ackerman LV. Distribution of colonic polyps: increased incidence of proximal lesions in older patients. Radiology. 1985; 155: 35-8.
125. Bond JH. Adenomatous polyps and adenocarcinoma of the colon. In: Dimarino AJ, Benjamin SB, editors. Gastrointestinal disease: an endoscopic approach. Oxford: Blackwell Science; 1997. p. 610-34.
126. Norgaard M, Iversen LH, Sorensen HT. Colorectal cancer. Incidence and risk factors. Ugeskr Laeger. 2005; 167 (44): 4157-9.
127. O’ Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Díaz B, et al. The National polyp study: patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology. 1990; 98: 371-90.
128. Arnold CN, Goel A, Blum HE, Baland CR. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer. 2005; 104 (10): 2035- 47.
129. Vogelstein B, Fearon ER, Hamilton SR, Kernse SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorrectal tumor development. New Engl J Med. 1988; 319: 525-32.
130. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-67.
131. Hardy RG, Meltzer SJ, Jankowski JA. Molecular basis for risk factors. ABC of colorectal cancer: clinical review. Br Med J. 2000; 321: 886-9.
132. Cruz-Bustillo D. Genética molecular del cáncer colorrectal. Rev Esp Enferm Dig (Madrid) 2004; 96(1): 48-59.
133. Lynch HT, Lynch JF. Genetics of colorectal cancer. Digestion 1998; 59: 481-92.